OncoMatch/Clinical Trials/NCT06431529
A Study of Tumor Neoantigen-specific T Cells in the Treatment of Advanced Solid Tumors
Is NCT06431529 recruiting? Yes, currently enrolling (May 2026). This Early Phase 1 trial studies tumor neoantigen specific T cell for tumor, solid.
Treatment: tumor neoantigen specific T cell — The goal of this clinical trial is to learn if tumor neoantigen-specific T cells can treat patients with advanced solid tumors. The main questions it aims to answer are: Evaluate the safety of intravenous infusion of tumor neoantigen-specific T cells in the treatment of advanced solid tumors such as ovarian cancer, non-small cell lung cancer, and colorectal cancer. To evaluate the effectiveness of intravenous infusion of tumor neoantigen-specific T cells in the treatment of advanced solid tumors such as ovarian cancer, non-small cell lung cancer, and colorectal cancer and to study its immunological properties in patients.
Check if I qualifyExtracted eligibility criteria
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: standard treatments
Cancer patients who have failed previous standard treatments or who have refused subsequent chemotherapy
Cannot have received: immunotherapy
received any form of immunotherapy within the past 3 months
Cannot have received: chemotherapy
received anti-tumor treatment such as tumor chemotherapy, radiotherapy, and secondary and above surgery within the past month
Cannot have received: radiotherapy
received anti-tumor treatment such as tumor chemotherapy, radiotherapy, and secondary and above surgery within the past month
Cannot have received: surgery
received anti-tumor treatment such as tumor chemotherapy, radiotherapy, and secondary and above surgery within the past month
Lab requirements
Blood counts
White blood cell count ≥ 3E9/L, platelet count ≥ 80E9/L
Kidney function
Creatinine clearance ≥ 60 ml/min
Liver function
AST and ALT ≤ 3×ULN, total bilirubin ≤ 2×ULN; AST and ALT ≤ 6×ULN in patients with liver metastasis
White blood cell count <3E9/L, platelet count <80E9/L; AST and ALT>3×ULN, total bilirubin>2×ULN, and AST and ALT>6×ULN in patients with liver metastasis; Creatinine clearance <60ml/min
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify